Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: Trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening

Transplant International

Volumn 13, Issue SUPPL. 1, 2000, Pages

  Ikonen, T S ^a   Gummert, J F ^a   Serkova, N ^b   Hayase, M ^a   Honda, Y ^a   Kobayase, Y ^a   Hausen, B ^a   Yock, P G ^a   Christians, U ^b   Morris, R E ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic rejection; Cyclosporine; Drug levels; Intravascular ultrasound; Non human primate; Sirolimus (rapamycin)

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ALLOTRANSPLANTATION; ANIMAL; AORTA; ARTICLE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECT; IMMUNOLOGY; INTIMA; MACACA; MALE; PATHOLOGY; REGRESSION ANALYSIS; TRANSPLANTATION;

ANIMALS; AORTA; CYCLOSPORINE; DISEASE PROGRESSION; IMMUNOSUPPRESSIVE AGENTS; MACACA FASCICULARIS; MALE; REGRESSION ANALYSIS; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUNICA INTIMA;

EID: 0000961614     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2000.tb02049.x     Document Type: Article

References (27)

1. Brazelton TR, Morris RE (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8: 710-720
2. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S (1989) Rapamycin for immunosuppression in organ allografting [letter] [see comments]. Lancet 2: 227
3. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE (1995) Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59: 390-395
4. DiJoseph JF, Fluhler E, Armstrong J, Sharr M, Sehgal SN (1996) Therapeutic blood levels of sirolimus rapamycin in the allografted rat. Transplantation 62: 1109-1112
5. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J (1993) The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 55: 340-345
6. Fuster V, Badimon L, Badimon JJ, Ip JH, Chesebro JH (1991) The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clin Proc 66: 818-831
7. Granger DK, Cromwell JW, Chen SC, Goswitz JJ, Morrow DT, Beierle FA, Sehgal SN, Canafax DM, Matas AJ (1995) Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59: 183-186
8. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE (1995) Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59: 655-661
9. Gregory CR, Huie P, Billingham ME, Morris RE (1993) Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55: 1409-1418
10. Gummert JF, Ikonen T, Briffa N, Honda Y, Hayase M, Perlroth J, Kobayashi Y, Hausen B, Barlow C, Billingham ME, Fitzgerald P, Yock PG, Robbins RC, Morris RE (1998) A new large-animal model for research of graft vascular disease. Transplant Proc 30: 4023
11. Hornick P, Smith J, Pomerance A, Mitchell A, Banner N, Rose M, Yacoub M (1997) Influence of acute rejection episodes, HLA matching, and donor/ recipient phenotype on the development of "early" transplant-associated coronary artery disease. Circulation 96:II-53
12. Ikonen TS, Gummert JF, Honda Y, Hayase M, Perlroth J, Hausen B, Barlow C, Fitzgerald P, Yock PG, Morris RE (1999) Development of models of graft vascular disease in nonhuman primates: evaluation of GVD by intravascular ultrasound in a new cynomolgus model with arterial allograft exchange. Transplant Proc 31: 687
13. Kahan BD (1998) Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 30: 2185-2188
14. Kahan BD, Murgia MG, Slaton J, Napoli K (1995) Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 17: 672-675
15. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT (1998) Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66: 1040-1046
16. Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76: 412-417
17. Meiser BM, Billingham ME, Morris RE (1991) Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease [see comments]. Lancet 338: 1297-1298
18. Morris RE (1993) Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann NY Acad Sci 685: 68-72
19. Morris RE, Meiser BM (1989) Identification of a new pharmacologic action for an old compound. Med Sci Res 17: 609-610
20. Ogunnaike HO, Starkey TD, Baldwin JC, Porter KA, Billingham ME, Jamieson SW (1987) An assessment of Nva2-cyclosporine in primate cardiac transplantation. Transplantation 43: 13-17
21. Panza A, Roslin MS, Coons M, Toporoff B, Strashun A, Alexandopoulous I, Chen CK, Chang T, Cunningham JN, Norin AJ (1991) One-year survival of heterotopic heart primate xenografts treated with total lymphoid irradiation and cyclosporine. Transplant Proc 23: 483-484
22. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR (1996) Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98: 2277-2283
23. Poston RS, Billingham ME, Hoyt GE, Pollard J, Shorthouse R, Morris RE, Robbins RC (1999) Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100 (in press)
24. Stepkowski SM, Chen H, Daloze P, Kahan BD (1991) Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 51: 22-26
25. Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD, Sewing KF (1996) Sensitive and specific quantification of sirolimus rapamycin and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 42: 1417-1425
26. Yakimets WJ, Lakey, Yatscoff RW, Katyal D, Ao Z, Finegood DT, Rajotte RV, Kneteman NM (1993) Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 56: 1293-1298
27. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J (1995) Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17: 666-671